April 7, 2025
Longevity Medical Institute™ (LMI), a leading centre for regenerative medicine and diagnostics in Mexico, has partnered with OncoInv to incorporate the OncoSeek® test into one of the most advanced and accessible cancer detection programs in Latin America.
OncoSeek® is a blood-based multi-cancer early detection (MCED) test that uses artificial intelligence to analyse protein tumour markers and estimate both the likelihood of cancer and its potential tissue of origin. It can detect 9 common types of cancer, including breast, lung, liver, colorectal, stomach, ovarian, pancreatic, oesophageal cancer, and lymphoma. The integration of OncoSeek® within LMI’s in-house clinical laboratory panel — which analyses over 70 key biomarkers, including PSA Total, PSA Free, CA 125, CA 15-3, and CA 19-9 — has created a robust and comprehensive cancer screening platform capable of detecting more than 12 types of cancer.
"Our goal is to offer personalised, preventive care that empowers patients to take control of their health,” said Dr Kirk Sanford, Founder of LMI. “This collaboration brings cutting-edge diagnostics to Mexico, in a streamlined and patient-friendly format."
Jesper Verhey, Commercial Director at OncoInv, noted, “Together, we’re making early cancer detection more comprehensive, accessible, and relevant for everyday clinical use.”
The integration of OncoSeek® into LMI’s services marks a major advancement in proactive cancer care — providing faster, more complete insights with a single blood draw, and supporting earlier intervention when it matters most.
